Solid organ transplantation requires immunosuppression, which renders organ recipients vulnerable to infections. Viral infections are common in pediatric heart transplants, especially parvovirus B19 (PVB19) infection, and independently increase risk of transplant failure \[[@CIT0001]\]. PVB19 preferentially infects erythroid progenitor cells, and chronic infection may induce bone marrow failure, including pure red-cell aplasia (PRCA), and various inflammatory disorders \[[@CIT0002]\]. PVB19 is largely contained by antibodies, but cytotoxic T cells also aid its control \[[@CIT0005]\]. In immunocompetent children, PVB19 causes a transient mild illness with a skin rash known as fifth disease or erythema infectiosum, whereas in immunocompromised individuals, infection can persist, resulting in chronic anemia, especially PRCA. Risk factors for chronic anemia due to PVB19 infection involve disorders or treatments compromising humoral and/or cell-mediated immunity, including congenital and acquired immunodeficiency syndromes, acute and chronic leukemias, antibody deficiencies, solid organ and bone marrow transplantation, and cancer chemotherapy and other immunosuppressive therapies \[[@CIT0003]\].

Parvovirus B19 was the most common viral genome detected in endomyocardial biopsies (83%) of pediatric heart transplant patients (n = 99), and chronic infection (\>6 months) was associated with early development of advanced transplant coronary artery disease, which can lead to graft rejection \[[@CIT0006]\]. PVB19 infection in transplant patients can cause significant morbidity, as 98% of such patients (n = 98) had anemia after solid organ and bone marrow transplantation \[[@CIT0007]\]. These cases require treatment with high-dose intravenous immunoglobulin (HD-IVIG; up to 2 g/kg/dose), as no specific antiviral treatment or enriched Ig product exists for PVB19 infection \[[@CIT0003]\]. In some cases, HD-IVIG is repeated for a prolonged period to suppress PVB19 viral load, and it is not uncommon for patients to develop complications such as aseptic meningitis. Few alternatives to HD-IVIG exist to treat these often recurring and debilitating complications in patients with heart transplant and parvovirus viremia.

Despite its numerous benefits for treating other illnesses, high-dose subcutaneous immunoglobulin (HD-SCIG) has not been approved for viral infections or other conditions requiring anti-inflammatory treatment, except for a rare autoimmune disorder, chronic inflammatory demyelinating polyneuropathy \[[@CIT0008]\]. The benefits of HD-SCIG include no venipuncture, self-administration at home, fewer systemic side effects, and more constant serum IgG levels \[[@CIT0009]\]. The latter effect might explain its improved efficacy relative to IVIG in some patients. For example, switching from HD-IVIG to HD-SCIG resolved aseptic meningitis associated with IVIG, improved the disease score, and decreased immunosuppressive therapy in a myasthenia gravis patient \[[@CIT0012]\]. Switching to SCIG also reduces fluid overload and hyperosmolarity, which benefits patients with fluid balance disorders such as renal failure \[[@CIT0011]\].

Recombinant human hyaluronidase (rHuPH20) degrades hyaluronan to expand the infusion capacity of subcutaneous tissue. Hyaluronidase administered with HD-SCIG enables higher dosing than HD-SCIG without hyaluronidase, thus decreasing the dosage interval \[[@CIT0013]\]. Dosage frequency can be as low as once per month, whereas nonfacilitated HD-SCIG is typically given every 1--2 weeks. Although the standard of care for pediatric heart transplant patients with chronic PVB19 infection is infusing HD-IG intravenously, we propose that the subcutaneous route may be a better option to control PVB19 viremia and reduce systemic side effects.

CASE SERIES {#s1}
===========

We present a cohort of three patients who received cardiac transplantation, complete thymectomy, and antithymocyte globulin in infancy and later acquired PVB19 infection that was treated with repeated HD-IVIG infusions. One patient (patient A) was more immunocompromised than the other two and did not respond to conventional treatment. This study was approved by the Institutional Review Board of Johns Hopkins All Children's Hospital.

Patient A is a 21-year-old male who underwent a heart transplant as a newborn for hypoplastic left heart syndrome, which was complicated by coarctation of the aorta. He also suffers from extensive chronic warts on his limbs, which remain refractory to medical treatment and are likely related to worsening T-cell lymphopenia. He also has severe chronic kidney disease (stage 4) with proteinuria as he awaits a kidney transplant.

Patients B and C are 10- and 11-year-old males, respectively, who received cardiac transplants due to pulmonary atresia and hypoplastic left heart syndrome, respectively. Patient B did not have any major surgical complications, whereas patient C developed post-transplant lymphoproliferative disorder and late severe acute rejection.

Two of the three patients (patients B and C) responded to HD-IVIG with undetectable PVB19 viral load, but patient A failed firstline HD-IVIG treatment as his viral load rebounded repeatedly ([Figure 1A](#F1){ref-type="fig"}). As this patient was refractory to treatment, our immunology team was consulted.

![Viral load in response to immunoglobulin treatment and T-cell counts of patients. A, Viral load of patients and immunoglobulin infusions. Blue arrowheads signify monthly dosage of high dose intravenous immunoglobulin infusions (1 g/kg per month), whereas brown arrowheads signify low dose subcutaneous (0.5 mg/kg) and green arrowheads indicate high dose subcutaneous immunoglobulin infusions (1 g/kg) per month. Stacked blue arrowheads indicate 2x dosage, whereas partially superimposed blue arrowheads indicate 1.5x dosage. NO IG (yellow arrow) indicates no immunoglobulin infusions. The high and low viral titers were rounded to \>1 000 000 and \<250 copies/mL, respectively. B, Mean total and naïve CD4^+^ T-cell counts of patients during treatment. C, Mean total and naïve CD8+ T-cell counts during treatment.](ofaa076f0001){#F1}

Immune evaluation ([Figure 1B](#F1){ref-type="fig"},[C](#F1){ref-type="fig"}) revealed that all three patients presented with abnormally low CD4+ T-cell counts, and two patients also had low CD8+ T cells (patients A and B). However, patient A exhibited more severe T-cell lymphopenia, especially with naïve T cells (average was 5 CD4+ cells/μL and 20 CD8+ cells/μL). Patient A also had severe aplastic anemia more than once (lowest hemoglobin 6.5 g/dL), whereas patients B and C had mild anemia (lowest hemoglobin 10.3 and 10.4 g/dL, respectively).

Patient A suffered from persistent PVB19 infection for \>7 years ([Figure 1A](#F1){ref-type="fig"}). He began treatment with HD-IVIG (1 g/kg) at age 14, which continued nearly 5 years. HD-IVIG treatment temporarily decreased his viral load, but he had recurring bouts of debilitating aseptic meningitis that led to frequent hospitalizations, requiring sedative pain control and spacing of HD-IVIG treatments. These episodes severely diminished his quality of life, so we considered an alternate route for administering IG. Hence, we began infusing SCIG at age 18 initially with a low dose (LD) injected weekly for 2 months (0.5 g/kg per month), however, rescue IVIG therapy was required for viral flares. Thus, to increase the dose of SCIG, we transitioned to HD hyaluronidase-facilitated SCIG (HD-SCIG-Hy), which was given at home every 2 weeks (1 g/kg per month) 3 months after beginning LD-SCIG. On this regimen, the patient required less rescue HD-IVIG, which ended three months after initiating HD-SCIG-Hy. Upon receiving HD-SCIG-Hy as the only Ig treatment, the patient no longer had aseptic meningitis and his viral load consistently dropped and remained below 1000 copies/μL. Consequently, treatment was stopped for a year but was reinitiated due to a rising viral load ([Figure 1A](#F1){ref-type="fig"}). During HD-IVIG treatment, his IgG trough levels varied between 542 and 2600 mg/dL; during HD-SCIG-Hy therapy, his IgG trough levels were 737--1590 mg/dL, and when treatment was withheld, they were 442--1060 mg/dL. Switching to HD-SCIG-Hy improved the patient's quality of life as it ceased hospitalizations for aseptic meningitis, reduced the variability of plasma IgG levels, decreased the quantity of IG given, and consequently lowered medical costs.

In contrast to patient A, patients B and C required short-term HD-IVIG, which consistently controlled their viral load ([Figure 1A](#F1){ref-type="fig"}) without inducing systemic adverse effects. Only one IgG trough level was recorded for patient B (828 mg/dL); IgG trough levels for patent C ranged between 417 and 1060 mg/dL. Patients B and C had considerably more CD4^+^ and CD8^+^ T cells ([Figure 1B](#F1){ref-type="fig"},[C](#F1){ref-type="fig"}) and required HD-IVIG infusions less frequently than patient A ([Figure 1A](#F1){ref-type="fig"}).

All three patients had normal total immunoglobulin G, A and M levels, but IgG levels were low occasionally for patients A and C. PVB19-specific antibody levels were not measured. All patients were maintained on mild oral immunosuppressive medications. Pharmacological immunosuppression was greatest in patient A, who received tacrolimus (1.5 mg daily) when he developed PVB19 viremia but was switched to sirolimus (1 mg/d) and mycophenolate (720 mg/d) due to renal insufficiency. Patient B received tacrolimus (2 mg/d) monotherapy. Patient C received sirolimus (0.8 mg/d) and prednisone (5 mg/every other day); in addition, tacrolimus (0.3 mg/d) was added when he developed late severe rejection.

DISCUSSION {#s2}
==========

Pediatric heart transplant patients often are fully thymectomized, which further suppresses their immunity and augments their susceptibility to infections such as PVB19. Our case series associates severe naïve T-cell lymphopenia with greater PVB19 load and decreased response to HD-IVIG. It is not surprising that viremia in patient A was less controlled with HD-IVIG than in patients B and C, as the former had significantly fewer T cells and received more immunosuppressive therapy. Nor is it unprecedented that switching from HD-IVIG to HD-SCIG-Hy resolved aseptic meningitis in patient A, as this has been reported previously \[[@CIT0008]\]. It is noteworthy, however, that switching from HD-IVIG to HD-SCIG-Hy markedly and continuously reduced the viral load in patient A. This may be due to the kinetics of maintaining more constant Ig levels through gradual diffusion in the hypodermis \[[@CIT0013]\].

Numerous studies underscore the importance of preserving the thymus as much as possible during pediatric cardiac operations. Avoidance of a full thymectomy during pediatric cardiac surgery facilitates normal T-cell development and adaptive immunity. Complete or near-complete thymectomy (\>90% removal) in pediatric patients (\<6 months old; n = 11) undergoing cardiac surgery led to considerable lymphopenia of CD4+ and CD8+ T cells and other abnormalities of cell-mediated immunity \[[@CIT0014]\]. Immunodeficiency due to early childhood thymectomy (\<5 years) impaired health outcomes several years later \[[@CIT0015]\].

Our case series is the first to report use of HD-SCIG-Hy to successfully treat chronic PVB19 in an immunosuppressed patient. A multicenter study is needed to determine if HD-SCIG is able to control PVB19 load more effectively and with fewer systemic side effects than HD-IVIG in other immunosuppressed patients. The mechanisms of viral control and kinetics of these two modalities should be further investigated *in vivo*. In conclusion, our report supports consideration of HD-SCIG-Hy early in the treatment of chronic PVB19 infection in pediatric cardiac transplant patients or other cases of persistent PVB19 infection with severe naïve T-cell lymphopenia.
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